Aris Persidis is president and cofounder of Biovista, a biotechnology company focusing on repositioning drugs.
He also participated in the cofounding of Cellzome (acquired by GSK), of Anadys (acquired by Roche), was co-founder and Managing Director of RheoGene (acquired by Intrexon), was senior vice president of business development of Upstate (acquired by Serologicals), and was vice president of business development and R&D of Upstate/Serologicals (acquired by Millipore).
Aris is a recipient of the Honeywell European Futurist Award, and has authored over 90 papers and book chapters, including the monthly Industry Trends column in Nature Biotechnology during its 3-year run. He currently also serves as Editor-in-Chief of the journal Drug Repurposing, Rescue, and Repositioning.
Prior to industry, Aris was an adjunct assistant professor at the Wharton Business School, where he also served as Assistant Director of the Medical School Technology Transfer Program. He has served as a judge for the 2011 Top-10 Innovations of The Scientist, and the 2013 Medical Media and Marketing Awards, and was the first chair of the Jefferson Corner Group, an angel investment group in Charlottesville, Virginia.
Aris holds a First Class B.Sc. degree in biological chemistry from Essex University, UK, and a Ph.D. in biochemistry from the University of Cambridge, UK.